U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164170) titled 'A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib' on Sept. 02.
Brief Summary: This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
Study Start Date: Oct. 25
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
DRUG: ABSK043 in combination with Glecirasib
Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose.
Based on the accumu...